A phase II study of adriamycin in previously untreated squamous cell carcinoma of the head and neck
- 1 December 1985
- Vol. 56 (11) , 2573-2575
- https://doi.org/10.1002/1097-0142(19851201)56:11<2573::aid-cncr2820561106>3.0.co;2-u
Abstract
Twenty patients with squamous cell carcinoma of the head and neck (SCC H/N) were treated with Adriamycin (doxorubicin) at a dosage of 60 mg/m2 at 3-week intervals. No patient had received surgery, radiation, or chemotherapy before treatment with Adriamycin. Responses were observed in 44% of 18 evaluable tumors. We conclude that Adriamycin is a highly active drug in SCC H/N when no prior treatment has been administered.This publication has 5 references indexed in Scilit:
- Adjuvant chemotherapy with Cis-diamminodichloroplatinum II and 120-hour infusion 5-fluorouracil in stage III and IV squamous cell carcinoma of the head and neckCancer, 1983
- Chemotherapy in Head and Neck CancerNew England Journal of Medicine, 1983
- Systemic chemotherapy of advanced head and neck malignanciesCancer, 1975
- Phase II evaluation of adriamycin in human neoplasiaCancer, 1973
- Adriamycin—an antitumor antibiotic in the treatment of neoplastic diseasesCancer, 1973